Key Takeaways
Cell therapies hold curative promise—but access remains limited. Scientific breakthroughs are outpacing the systems needed to deliver them, including reimbursement models, manufacturing infrastructure, and traditional biotech business frameworks.
Rare and ultra-rare diseases require new development models. With over 10,000 rare diseases identified and only a small fraction having approved treatments, innovative funding, nonprofit-driven, and collaborative approaches are essential to expand patient access.
Manufacturing inefficiencies are slowing progress. Siloed, proprietary approaches to process development increase costs and timelines. Greater collaboration and shared manufacturing knowledge could significantly improve efficiency and scalability.
Payer and reimbursement challenges remain a major barrier. One-time, high-cost therapies do not align well with existing insurance models, driving the need for outcomes-based agreements, risk-sharing structures, and government-led reimbursement initiatives.
Early alignment across stakeholders is critical. Connecting developers, CDMO partners, patient advocacy groups, regulators, and payers early in development helps de-risk programs and accelerate the path from concept to clinic.
New regulatory and funding frameworks are emerging. Initiatives such as platform-based regulatory pathways and CMS-led payment models signal meaningful progress toward making advanced therapies more accessible and sustainable.
To dive deeper into these insights and perspectives, read the full article here.
